Search Results - "Oxnard, Geoffrey R"

The cellular origins of drug resistance in cancer by Oxnard, Geoffrey R

“…Two new studies show that mechanisms of acquired resistance to targeted therapy in lung cancer do not necessarily pre-exist in resistant subclones. Instead,…”
Get full text

New Targetable Oncogenes in Non–Small-Cell Lung Cancer by Oxnard, Geoffrey R, Binder, Adam, Jaenne, Pasi A

“…The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase…”
Get full text

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions by Cheng, Michael L., Pectasides, Eirini, Hanna, Glenn J., Parsons, Heather A., Choudhury, Atish D., Oxnard, Geoffrey R.

“…The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid…”
Get full text

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M by Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R

“…A mutation conferring resistance to novel irreversible EGFR inhibitors is identified in cell-free plasma DNA from lung cancer patients. Here we studied…”
Get full text

False positive plasma genotyping due to clonal hematopoiesis by Hu, Yuebi, Ulrich, Bryan, Supplee, Julianna, Kuang, Yanan, Lizotte, Patrick H, Feeney, Nora, Guibert, Nicolas, Awad, Mark M, Wong, Kwok-Kin, Janne, Pasi A, Paweletz, Cloud Peter, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy is debated. Because most cfDNA is derived from peripheral blood…”
Get full text

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA by OXNARD, Geoffrey R, PAWELETZ, Cloud P, JÄNNE, Pasi A, YANAN KUANG, MACH, Stacy L, O'CONNELL, Allison, MESSINEO, Melissa M, LUKE, Jason J, BUTANEY, Mohit, KIRSCHMEIER, Paul, JACKMAN, David M

“…Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome…”
Get full text

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice by Aggarwal, Charu, Rolfo, Christian D., Oxnard, Geoffrey R., Gray, Jhanelle E., Sholl, Lynette M., Gandara, David R.

“…Upfront tumour genotyping is now considered an essential step in guiding treatment decision-making in the management of patients with advanced-stage…”
Get full text

Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review by Sacher, Adrian G, Komatsubara, Kimberly M, Oxnard, Geoffrey R

“…The rational treatment of metastatic NSCLC hinges on the timely detection of potentially targetable genomic alterations to guide therapy. Recent advances in…”
Get more information

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer by OXNARD, Geoffrey R, ARCILA, Maria E, CHMIELECKI, Juliann, LADANYI, Marc, MILLER, Vincent A, PAO, William

“…The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal…”
Get full text

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC by Aerts, Hugo J. W. L., Grossmann, Patrick, Tan, Yongqiang, Oxnard, Geoffrey R., Rizvi, Naiyer, Schwartz, Lawrence H., Zhao, Binsheng

“…Medical imaging plays a fundamental role in oncology and drug development, by providing a non-invasive method to visualize tumor phenotype. Radiomics can…”
Get full text

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies by Solomon, Benjamin J, Tan, Lavinia, Lin, Jessica J, Wong, Stephen Q, Hollizeck, Sebastian, Ebata, Kevin, Tuch, Brian B, Yoda, Satoshi, Gainor, Justin F, Sequist, Lecia V, Oxnard, Geoffrey R, Gautschi, Oliver, Drilon, Alexander, Subbiah, Vivek, Khoo, Christine, Zhu, Edward Y, Nguyen, Michele, Henry, Dahlia, Condroski, Kevin R, Kolakowski, Gabrielle R, Gomez, Eliana, Ballard, Joshua, Metcalf, Andrew T, Blake, James F, Dawson, Sarah-Jane, Blosser, Wayne, Stancato, Louis F, Brandhuber, Barbara J, Andrews, Steve, Robinson, Bruce G, Rothenberg, S Michael

“…Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors…”
Get more information

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma by Reckamp, Karen L, Melnikova, Vladislava O, Karlovich, Chris, Sequist, Lecia V, Camidge, D Ross, Wakelee, Heather, Perol, Maurice, Oxnard, Geoffrey R, Kosco, Karena, Croucher, Peter, Samuelsz, Errin, Vibat, Cecile Rose, Guerrero, Shiloh, Geis, Jennifer, Berz, David, Mann, Elaina, Matheny, Shannon, Rolfe, Lindsey, Raponi, Mitch, Erlander, Mark G, Gadgeel, Shirish

“…In approximately 60% of patients with NSCLC who are receiving EGFR tyrosine kinase inhibitors, resistance develops through the acquisition of EGFR T790M…”
Get more information

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients by Paweletz, Cloud P, Sacher, Adrian G, Raymond, Chris K, Alden, Ryan S, O'Connell, Allison, Mach, Stacy L, Kuang, Yanan, Gandhi, Leena, Kirschmeier, Paul, English, Jessie M, Lim, Lee P, Jänne, Pasi A, Oxnard, Geoffrey R

“…Tumor genotyping is a powerful tool for guiding non-small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically…”
Get full text

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations by REKHTMAN, Natasha, PAIK, Paul K, ARCILA, Maria E, TAFE, Laura J, OXNARD, Geoffrey R, MOREIRA, Andre L, TRAVIS, William D, ZAKOWSKI, Maureen F, KRIS, Mark G, LADANYI, Marc

“…There is persistent controversy as to whether EGFR and KRAS mutations occur in pulmonary squamous cell carcinoma (SQCC). We hypothesized that the reported…”
Get full text

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial by Subbiah, Vivek, Gainor, Justin F, Oxnard, Geoffrey R, Tan, Daniel S W, Owen, Dwight H, Cho, Byoung Chul, Loong, Herbert H, McCoach, Caroline E, Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y, Kherani, Jennifer F, Huang, Xin, Kang, Suhyun, Drilon, Alexander

“…We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for fusion-positive non-small…”
Get full text

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations by Carrot-Zhang, Jian, Soca-Chafre, Giovanny, Patterson, Nick, Thorner, Aaron R, Nag, Anwesha, Watson, Jacqueline, Genovese, Giulio, Rodriguez, July, Gelbard, Maya K, Corrales-Rodriguez, Luis, Mitsuishi, Yoichiro, Ha, Gavin, Campbell, Joshua D, Oxnard, Geoffrey R, Arrieta, Oscar, Cardona, Andres F, Gusev, Alexander, Meyerson, Matthew

“…Inherited lung cancer risk, particularly in nonsmokers, is poorly understood. Genomic and ancestry analysis of 1,153 lung cancers from Latin America revealed…”
Get more information

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors by Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M, Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E, Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J, Bahcall, Magda, Oxnard, Geoffrey R, Eck, Michael J, Jänne, Pasi A

“…Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these…”
Get full text

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions by Oxnard, Geoffrey R, Lo, Peter C, Nishino, Mizuki, Dahlberg, Suzanne E, Lindeman, Neal I, Butaney, Mohit, Jackman, David M, Johnson, Bruce E, Jänne, Pasi A

“…Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is…”
Get more information

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA by Supplee, Julianna G., Milan, Marina S.D., Lim, Lee P., Potts, Kristy T., Sholl, Lynette M., Oxnard, Geoffrey R., Paweletz, Cloud P.

“…•Next-generation sequencing (NGS) of cell-free DNA could expand access to precision medicine.•Technical differences between plasma NGS assays are poorly…”
Get full text

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer by Yasuda, Hiroyuki, Park, Eunyoung, Yun, Cai-Hong, Sng, Natasha J, Lucena-Araujo, Antonio R, Yeo, Wee-Lee, Huberman, Mark S, Cohen, David W, Nakayama, Sohei, Ishioka, Kota, Yamaguchi, Norihiro, Hanna, Megan, Oxnard, Geoffrey R, Lathan, Christopher S, Moran, Teresa, Sequist, Lecia V, Chaft, Jamie E, Riely, Gregory J, Arcila, Maria E, Soo, Ross A, Meyerson, Matthew, Eck, Michael J, Kobayashi, Susumu S, Costa, Daniel B

“…Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine…”
Get more information